Squamous Cell Carcinoma Antigen in Follow-Up of Cervical Cancer Treated With Radiotherapy: Evaluation of Cost-Effectiveness

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1145-1149

  Forni, Franca ^a   Ferrandina, Gabriella ^a,b   Deodato, Francesco ^b   Macchia, Gabriella ^b   Morganti, Alessio G ^a,b   Smaniotto, Daniela ^a   Luzi, Stefano ^a   D'Agostino, Giuseppe ^a   Valentini, Vincenzo ^a   Cellini, Numa ^a   Giardina, Bruno ^a   Scambia, Giovanni ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cervical cancer; Cost analysis; Follow up; Radiotherapy; SCC; Squamous cell carcinoma

Indexed keywords

ANTIGENS; CELLS; COST EFFECTIVENESS; DIAGNOSIS; DISEASES; MEDICAL IMAGING; RADIOTHERAPY; SURGERY;

CERVICAL CANCER; CLINICORADIOLOGIC; COST ANALYSIS; SQUAMOUS CELL CARCINOMA;

ONCOLOGY;

SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HEALTH CARE COST; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PRIORITY JOURNAL; THORAX RADIOGRAPHY; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 35449000190     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.055     Document Type: Article

References (21)

1. Parkin D.M., Whelan S.L., and Ferlay J. Cancer incidence in five continents. Vol VII. International Agency for Research on Cancer, Scientific Publications No.143 (1997), IARC, Lyon
2. Jemal A., Thomas A., Murray T., et al. Cancer statistics. CA Cancer J Clin 52 (2002) 23-24
3. Kew F.M., Roberts A.P., and Cruickshank D.J. The role of routine follow up after gynecologic malignancy. Int J Gynecol Cancer 15 (2005) 415-419
4. Scambia G., Benedetti Panici P., Foti E., et al. Squamous cell carcinoma antigen: Prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 12 (1994) 2309-2316
5. Reesink-Peters N., van der Velden J., ten Hoor K.A., et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early stage cervical cancer. J Clin Oncol 23 (2005) 1455-1462
6. Takeda M., Sakaragi N., Okamoto K., et al. Preoperative serum SCC, CA 125 and CA 19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 81 (2002) 451-457
7. Molina R., Filella X., Lejarcegui J.A., et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol 24 (2003) 156-164
8. Ohno T., Nakayama Y., Nakamoto S., et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 97 (2003) 3114-3120
9. Micke O., Prott F.J., Schafer U., et al. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 20 (2000) 5113-5115
10. Bolger B.S., Dabbas M., Lopes A., et al. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 65 (1997) 309-313
11. Hong J.H., Tsai C.S., Chang J.T., et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 41 (1998) 823-830
12. Pras E., Willemse P.H., Canrinus A.A., et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys 52 (2002) 23-32
13. Esajas M.D., Duk J.M., de Bruijn H.W., et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 19 (2001) 3960-3966
14. Chan Y.M., Ng T.Y., Ngan H.Y.S., et al. Monitoring of serum squamous cell antigen levels in invasive cervical cancer: Is it cost effective?. Gynecol Oncol 84 (2002) 7-11
15. Peters W.A., Liu P.Y., Barretyt R.J., et al. Concurrent chemotherapy and pelvic radiation compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix. J Clin Oncol 79 (2000) 485-489
16. Mancuso S., Smaniotto D., Benedetti Panici P., et al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 78 (2000) 324-328
17. Distefano M., Fagotti A., Ferrandina G., et al. Preoperative chemoradiotherapy in locally advanced cervical cancer: Long term outcome and complications. Gynecol Oncol 1 (2005) S166-S170
18. Abe A., Nakano T., Morita S., et al. Clinical evaluation of serum and immunohistochemical expression of SCC in radiation therapy for cervical cancer. Anticancer Res 19 (1999) 829-836
19. Marnitz S., Kohler C., Muller M., et al. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 103 (2006) 1023-1030
20. Teran-Porcayo M.A., Zeichner-Gancz I., del Castillo R.A., et al. Pelvic exenteration for recurrent or persistent cervical cancer: Experience of five years at the National Cancer Institute in Mexico. Med Oncol 23 (2006) 219-223
21. Duk J.M., de Bruijn H.W., Groenier K.H., et al. Cancer of uterine cervix: Sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 34 (1990) 186-194